| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.12.23 | Biomea Fusion, Inc.: Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts | 201 | GlobeNewswire (Europe) | At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100... ► Artikel lesen | |
| 09.12.23 | FibroGen, Inc.: FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting | 324 | GlobeNewswire (Europe) | A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence = 56 days with roxadustat vs. placebo (36.1% vs... ► Artikel lesen | |
| 09.12.23 | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) | 203 | GlobeNewswire (Europe) | Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting =1 point improvement on PGIS by week 20 100% of bezuclastinib treated... ► Artikel lesen | |
| 09.12.23 | TScan Therapeutics, Inc.: TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition | 132 | GlobeNewswire (Europe) | No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical intervention... ► Artikel lesen | |
| 09.12.23 | Century Therapeutics, Inc.: Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits | 141 | GlobeNewswire (Europe) | - Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient - - Preliminary... ► Artikel lesen | |
| 09.12.23 | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial | 191 | GlobeNewswire (Europe) | Anti-tumor activity and durability of responses data support advancement of soquelitinib (formerly known as CPI-818) into Phase 3 registrational clinical trial and its potential to address the need... ► Artikel lesen | |
| 09.12.23 | X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023 | 225 | GlobeNewswire (Europe) | Initial data continue to support advancement of mavorixafor into pivotal, global Phase 3 trial in certain chronic neutropenic disorders; company on track to initiate in 1H 2024 X4 expects to present... ► Artikel lesen | |
| 09.12.23 | Allogene Therapeutics, Inc.: Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology | 221 | GlobeNewswire (Europe) | Comprehensive Review of All Patients in the Phase 1 ALPHA/ALPHA2 Trials Demonstrate that Adding Investigational ALLO-647 to Standard Lymphodepletion Can Yield Durable Responses and a Safety Profile... ► Artikel lesen | |
| 09.12.23 | Bulletin from Annual General Meeting in SkiStar AB | 146 | GlobeNewswire (Europe) | At SkiStar AB (publ)'s annual general meeting, held in Sälen on 9 December 2023, the following decisions were made. A dividend of SEK 2.60 per share was adopted. Record day 12 December 2023.Lena... ► Artikel lesen | |
| 09.12.23 | Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ in Patients with Blood Cancers at the 65th ASH Annual Meeting | 190 | GlobeNewswire (Europe) | Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer careNew data demonstrates MRD assessed from blood in multiple myeloma may be an indicator... ► Artikel lesen | |
| 09.12.23 | Borregaard ASA: Operational issues and lower biovanillin demand in the 4th quarter | 206 | GlobeNewswire (Europe) | During the 4th quarter of 2023, operational issues have affected production at the Sarpsborg site, reducing the result mainly in BioMaterials. Following the annual maintenance stop in October, the... ► Artikel lesen | |
| 09.12.23 | Galapagos NV: Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 | 797 | GlobeNewswire (Europe) | Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo... ► Artikel lesen | |
| 09.12.23 | F. Hoffmann-La Roche Ltd: New data reinforce the benefit of early preventative treatment with Roche's Hemlibra for babies with severe haemophilia A | 715 | GlobeNewswire (Europe) | Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years... ► Artikel lesen | |
| 09.12.23 | Alaska Energy Metals Corporation: Alaska Energy Metals Announces Flow-Through Financing; Acquisition Update and IR Developments | 491 | GlobeNewswire (Europe) | Highlights: Alaska Energy Metals Corporation announces intention to conduct a non-brokered flow-through private placementThe TSX Venture Exchange has issued a bulletin publishing its acceptance of... ► Artikel lesen | |
| 09.12.23 | Nasdaq, Inc.: Annual Changes to the Nasdaq-100 Index | 436 | GlobeNewswire (Europe) | NEW YORK, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (Nasdaq: NDX), which will become effective prior... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 504 |
| BAYER | 328 |
| BYD | 290 |
| NEL | 268 |
| NVIDIA | 249 |
| PLUG POWER | 237 |
| TUI | 224 |
| TESLA | 223 |
| DEUTSCHE BANK | 220 |
| SUPER MICRO COMPUTER | 217 |
| APPLE | 207 |
| RHEINMETALL | 191 |
| RWE | 183 |
| DEUTSCHE LUFTHANSA | 176 |
| AMAZON | 172 |
| MERCEDES-BENZ | 171 |
| BERKSHIRE HATHAWAY | 157 |
| COMMERZBANK | 136 |
| RENK GROUP | 136 |
| VOLKSWAGEN | 136 |
| BIONTECH | 135 |
| AIXTRON SE | 132 |
| BASF | 132 |
| PAYPAL | 131 |
| ALLIANZ | 130 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
